TriSalus Life Sciences, Inc.
TLSIWNasdaq
$0.86
↑ +6.3%Jul 17 close · end-of-day
Price
1Y↓ -46.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$45.0M
Enterprise Value
$21.5M
P/E
—
P/S
1.0
P/B
3.5
EV/EBITDA
—
PEG
—
FCF Yield
-45.1%
Dividend Yield
—
Revenue (TTM)
$44.9M
Net Income (TTM)
-$27.3M
Free Cash Flow (TTM)
-$20.3M
Gross Margin
85.1%
Operating Margin
-62.5%
Net Margin
-60.9%
ROE
-213.3%
ROIC
—
Debt / Equity
2.6
Net Cash
$23.5M
Return 1Y
-46.2%
Company profile
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
- CEO
- Mary T. Szela
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 106
- Headquarters
- Colorado
- Website
- trisaluslifesci.com
Earnings
TLSIW Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$8.9M↓ -2.9%
Diluted EPS$0.03↓ -107.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $12.4M | $18.5M | $29.4M | $45.2M |
| Gross profit | — | $10.1M | $15.9M | $25.3M | $38.2M |
| Operating income | -$3.0M | -$36.4M | -$54.5M | -$36.2M | -$26.9M |
| Net income | $4.8M | -$47.2M | -$59.4M | -$30.0M | -$39.2M |
| Diluted EPS | — | -$161.55 | -$6.77 | -$1.31 | -$1.84 |
| Operating cash flow | -$1.7M | -$32.3M | -$50.6M | -$40.8M | -$18.0M |
| Free cash flow | — | -$33.0M | -$51.2M | -$41.2M | -$18.9M |
| Gross margin | — | 81.8% | 85.9% | 86.1% | 84.6% |
| Operating margin | — | -293.9% | -294.3% | -122.9% | -59.7% |
| Net margin | — | -380.6% | -320.7% | -102.1% | -86.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.4M | $7.3M | $8.3M | $9.2M | $11.2M | $11.6M | $13.2M | $8.9M |
| Gross profit | $6.5M | $6.3M | $7.0M | $7.7M | $9.4M | $9.7M | $11.4M | $7.7M |
| Operating income | -$8.2M | -$8.7M | -$7.6M | -$7.3M | -$7.3M | -$9.0M | -$3.3M | -$8.4M |
| Net income | -$4.3M | -$2.4M | -$10.1M | -$10.4M | -$8.3M | -$10.8M | -$9.8M | $1.5M |
| Diluted EPS | -$0.21 | -$0.12 | -$0.38 | -$0.39 | -$0.27 | -$0.96 | -$0.22 | $0.03 |
| Operating cash flow | -$13.4M | -$10.8M | -$5.7M | -$4.5M | -$7.3M | -$3.7M | -$2.5M | -$6.5M |
| Free cash flow | -$13.5M | -$11.0M | -$5.8M | -$5.3M | -$7.4M | -$3.9M | -$2.5M | -$6.6M |
| Gross margin | 87.6% | 86.3% | 85.3% | 83.7% | 83.9% | 83.5% | 86.7% | 86.2% |
| Operating margin | -111.0% | -118.9% | -91.8% | -79.9% | -65.4% | -77.9% | -24.8% | -94.5% |
| Net margin | -58.8% | -32.6% | -122.4% | -113.2% | -73.9% | -93.5% | -73.9% | 17.3% |
Company news
Jul 16, 2026
May 13, 2026
May 12, 2026
- 68d agoTriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimatesfinance.yahoo.com
- 69d agoTriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growthfinance.yahoo.com
- 69d agoReal-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidancefinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.